Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Prospective Open-label Clinical Trial of the Safety and Efficacy of Amidine Hydrochloride (DD217) in Prevention of Thrombotic Complications in Hospitalized Patients Diagnosed With COVID-19

NCT05185804 is registered in ClinicalTrials.gov with PharmaDiall Ltd. as lead sponsor.

NCT NCT05185804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05185804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Prospective Open-label Clinical Trial of the Safety and Efficacy of Amidine Hydrochloride (DD217) in Prevention of Thrombotic Complications in Hospitalized Patients Diagnosed With COVID-19
Lead sponsor
PharmaDiall Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 8, 2021
Completion date
October 29, 2021
Enrollment
399 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, venous thromboembolism